These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 10825126)
1. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Scheffer GL; Maliepaard M; Pijnenborg AC; van Gastelen MA; de Jong MC; Schroeijers AB; van der Kolk DM; Allen JD; Ross DD; van der Valk P; Dalton WS; Schellens JH; Scheper RJ Cancer Res; 2000 May; 60(10):2589-93. PubMed ID: 10825126 [TBL] [Abstract][Full Text] [Related]
2. Flow cytometric analysis of breast cancer resistance protein expression and function. Minderman H; Suvannasankha A; O'Loughlin KL; Scheffer GL; Scheper RJ; Robey RW; Baer MR Cytometry; 2002 Jun; 48(2):59-65. PubMed ID: 12116365 [TBL] [Abstract][Full Text] [Related]
3. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629 [TBL] [Abstract][Full Text] [Related]
4. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Schellens JH; Maliepaard M; Scheper RJ; Scheffer GL; Jonker JW; Smit JW; Beijnen JH; Schinkel AH Ann N Y Acad Sci; 2000; 922():188-94. PubMed ID: 11193894 [TBL] [Abstract][Full Text] [Related]
5. [Drug-resistant proteins in breast cancer: recent progress in multidrug resistance]. Wu DL; Huang F; Lu HZ Ai Zheng; 2003 Apr; 22(4):441-4. PubMed ID: 12704006 [TBL] [Abstract][Full Text] [Related]
6. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043 [TBL] [Abstract][Full Text] [Related]
7. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Maliepaard M; Scheffer GL; Faneyte IF; van Gastelen MA; Pijnenborg AC; Schinkel AH; van De Vijver MJ; Scheper RJ; Schellens JH Cancer Res; 2001 Apr; 61(8):3458-64. PubMed ID: 11309308 [TBL] [Abstract][Full Text] [Related]
8. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Shepard RL; Cao J; Starling JJ; Dantzig AH Int J Cancer; 2003 Jan; 103(1):121-5. PubMed ID: 12455064 [TBL] [Abstract][Full Text] [Related]
9. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells]. Zhang YH; Li G; Yu J; Xu MS; Liu ZX Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902 [TBL] [Abstract][Full Text] [Related]
11. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Maliepaard M; van Gastelen MA; de Jong LA; Pluim D; van Waardenburg RC; Ruevekamp-Helmers MC; Floot BG; Schellens JH Cancer Res; 1999 Sep; 59(18):4559-63. PubMed ID: 10493507 [TBL] [Abstract][Full Text] [Related]
12. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies. Zhou XF; Yang X; Wang Q; Coburn RA; Morris ME Drug Metab Dispos; 2005 Aug; 33(8):1220-8. PubMed ID: 15908473 [TBL] [Abstract][Full Text] [Related]
13. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase. Ji N; Yuan J; Liu J; Tian S Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767 [TBL] [Abstract][Full Text] [Related]
14. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). Ma MT; He M; Wang Y; Jiao XY; Zhao L; Bai XF; Yu ZJ; Wu HZ; Sun ML; Song ZG; Wei MJ Cancer Lett; 2013 Oct; 339(1):107-15. PubMed ID: 23879965 [TBL] [Abstract][Full Text] [Related]
15. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line. Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232 [TBL] [Abstract][Full Text] [Related]
16. Selection and characterization of a high-activity ribozyme directed against the antineoplastic drug resistance-associated ABC transporter BCRP/MXR/ABCG2. Kowalski P; Wichert A; Holm PS; Dietel M; Lage H Cancer Gene Ther; 2001 Mar; 8(3):185-92. PubMed ID: 11332989 [TBL] [Abstract][Full Text] [Related]
17. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Doyle L; Ross DD Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842 [TBL] [Abstract][Full Text] [Related]
18. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. Ross DD; Yang W; Abruzzo LV; Dalton WS; Schneider E; Lage H; Dietel M; Greenberger L; Cole SP; Doyle LA J Natl Cancer Inst; 1999 Mar; 91(5):429-33. PubMed ID: 10070941 [TBL] [Abstract][Full Text] [Related]
19. The role of breast cancer resistance protein in acute lymphoblastic leukemia. Plasschaert SL; van der Kolk DM; de Bont ES; Kamps WA; Morisaki K; Bates SE; Scheffer GL; Scheper RJ; Vellenga E; de Vries EG Clin Cancer Res; 2003 Nov; 9(14):5171-7. PubMed ID: 14613996 [TBL] [Abstract][Full Text] [Related]
20. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2). Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]